Canaccord Genuity Reiterates Hold on Protalix BioTherapeutics (PLX)

Analysts at Canaccord Genuity Reiterated their Hold rating on Protalix BioTherapeutics (NYSE: PLX) with a price target of $6.00.

The $6 price target reflects modest US but robust Israel & ROW sales potential, said an analyst at Canaccord Genuity.

"EU launch delayed to 2016. We think PLX/partner Pfizer's Elelyso (taliglucerase) may ultimately get ~15% of the $1.2B+ worldwide Gaucher's market. Our target is based on a DCF of projected US/ROW sales and pNPV of future EU sales."

For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.

Shares of Protalix BioTherapeutics closed at $5.73 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
• SoundThinking (SSTI) PT Lowered to $8 at Cantor Fitzgerald
• McGraw Hill (MH) PT Raised to $15 at UBS